TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06935370: EASi-HF Reduced - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Emp

Sponsor: Boehringer Ingelheim · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 4200 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$10,843,120

Rescue Site Savings

+$7,165,888

Unlock Full NCT06935370 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06935370 Rescue Dossier →